Radio-frequency ablation of unresectable hepatic and renal tumors has achieved considerable success, but the technique has not been widely tested in other organs. RFA may considerably reduce the size of advanced tumors in the mouth and throat and alleviate pain, according to a pioneering study by a New York City group.
Radio-frequency ablation of unresectable hepatic and renal tumors has achieved considerable success, but the technique has not been widely tested in other organs. RFA may considerably reduce the size of advanced tumors in the mouth and throat and alleviate pain, according to a pioneering study by a New York City group.
Researchers at Albert Einstein College of Medicine's Montefiore Medical Center treated seven tumors in six patients in a preliminary report published in the August issue of Head and Neck. Tumor size ranged from 2 to 15 cm, with masses located on the tongue, oropharynx, neck, and elsewhere. All patients reported significant pain relief. Given the tumors' locations, ultrasound wasn't nearly as useful as a laryngoscope for guiding treatment, but MR and CT identified tumors and guided planning for the procedures. Here, CT shows a peritonsillar mass. While the procedure has proved safe so far, collateral damage to surrounding tissue and cranial nerves remains a concern. Though RFA is for now a palliative measure, it could turn out to be a curative technique, the authors said.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.